| Peer-Reviewed

Advances in the Combination Therapy of Targeted Anti-Cancer Drugs

Received: 16 May 2016     Published: 18 May 2016
Views:       Downloads:
Abstract

The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.

Published in Science Discovery (Volume 4, Issue 2)
DOI 10.11648/j.sd.20160402.17
Page(s) 94-98
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2016. Published by Science Publishing Group

Keywords

Cancer, Drug, Target, Combination Therapy

References
[1] 世卫组织预计到2030年癌症死亡人数可能翻番,生物学通报,2010年第45卷第03期,25。
[2] 胡胜等,癌症靶向药物的联合治疗,药品评价,2012年第9卷第21期,28-35。
[3] Mendelsohn J, et al., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21(14): 2787-2799.
[4] 王勐等,厄洛替尼与西妥昔单抗联合应用治疗吉非替尼耐药N S C L C 的疗效,中国肿瘤临床,2011年第38卷第24期,1505-1509。
[5] 韦玮等,西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用,癌症,2008年第4期,386-392。
[6] Miller KD, et al., Randomized phase Ⅲ trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J. Clin. Oncol., 2005, 23(4): 792-799.
[7] Blackwell KL, et al., Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer, J. Clin. Oncol., 2010, 28(7): 1124-1130.
[8] 江秉华 等,CN101332301A,2008年12月31日。
[9] Wymann, M. P.,et al., Phosphoinositide 3-kinase signalling –which way to target Trends Pharmacol. Sci., 2003, 24(7): 366-376.
[10] Cantley, C. C., et al., New insights into tumor suppression: PTEN suppresses tumorformation by restraining the phosphoinositide 3-kinaseyAKT pathway, Proc. Natl. Acad. Sci., 1999, 96: 4240-4245.
[11] Engelman, J. A., Targeting PI3K signalling in cancer:opportunities, challenges andlimitations, Nature Reviews/Cancer, 2009, 9: 550-562.
[12] Kozma, S. C. et al., Regulation of cell size in growth,development and human disease:PI3K, PKB and S6K, Bioessays, 2002, 24: 65-71.
[13] Takeuchi H., et al., Synergistic Augmentation of Rapamycin-Induced Autophagyin Malignant Glioma Cells by Phosphatidylinositol3-Kinase/Protein Kinase B Inhibitors, Cancer Res., 2005, 65(8): 3336-3346.
[14] Sun S.Y., et al., Activation of Akt and eIF4E Survival Pathways byRapamycin-Mediated Mammalian Target of RapamycinInhibition, Cancer Res., 2005, 65(16): 7052-7058.
[15] BURSAVICH M., et al.,WO2006044453A1, 2006年4月27日。
[16] GARCIA E. C.,et al.,WO2010049481A1, 2010年5月6日。
[17] FRITSCH C., et al.,WO2012148846 A1, 2012年11月1日。
[18] GUO X., et al.,WO2012148540 A1, 2012年11月1日。
[19] B. Markman, et al., Status of PI3K inhibition and biomarker development in cancer therapeutics, Ann. Oncol., 2009, 21(4): 683-691.
[20] KLINGHOFFER R., et al.,WO2010120599 A2 2010年10月21日。
[21] TAN J., et al.,WO2011084108 A1, 2011年7月14日。
[22] LEE C. J., et al., WO2009036101A1, 2009年3月19日。
[23] AFTAB D., et al., WO2008021389 A2,2008年2月21日。
[24] FRITSCH C., et al., WO2010006225 A1, 2010年1月14日。
[25] DUMBLE M., et al., WO2011038082 A1, 2011年3月31日。
[26] DUMBLE M., et al., WO2011038085 A1, 2011年3月31日。
[27] BEL V. M., et al., WO2011054620 A1, 2011年5月12日。
[28] BIHONGNEU O. A., et al., WO2013037943 A1, 2013年3月21日。
[29] GILMER T., et al., WO2011062930A1, 2011年5月26日。
Cite This Article
  • APA Style

    Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng. (2016). Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Science Discovery, 4(2), 94-98. https://doi.org/10.11648/j.sd.20160402.17

    Copy | Download

    ACS Style

    Jie Yang; Yan Wu; Zhen Wu; Yong-Tao Cui; Xiao-Qi Peng. Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Sci. Discov. 2016, 4(2), 94-98. doi: 10.11648/j.sd.20160402.17

    Copy | Download

    AMA Style

    Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng. Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Sci Discov. 2016;4(2):94-98. doi: 10.11648/j.sd.20160402.17

    Copy | Download

  • @article{10.11648/j.sd.20160402.17,
      author = {Jie Yang and Yan Wu and Zhen Wu and Yong-Tao Cui and Xiao-Qi Peng},
      title = {Advances in the Combination Therapy of Targeted Anti-Cancer Drugs},
      journal = {Science Discovery},
      volume = {4},
      number = {2},
      pages = {94-98},
      doi = {10.11648/j.sd.20160402.17},
      url = {https://doi.org/10.11648/j.sd.20160402.17},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20160402.17},
      abstract = {The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.},
     year = {2016}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Advances in the Combination Therapy of Targeted Anti-Cancer Drugs
    AU  - Jie Yang
    AU  - Yan Wu
    AU  - Zhen Wu
    AU  - Yong-Tao Cui
    AU  - Xiao-Qi Peng
    Y1  - 2016/05/18
    PY  - 2016
    N1  - https://doi.org/10.11648/j.sd.20160402.17
    DO  - 10.11648/j.sd.20160402.17
    T2  - Science Discovery
    JF  - Science Discovery
    JO  - Science Discovery
    SP  - 94
    EP  - 98
    PB  - Science Publishing Group
    SN  - 2331-0650
    UR  - https://doi.org/10.11648/j.sd.20160402.17
    AB  - The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.
    VL  - 4
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China

  • Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China

  • Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China

  • Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China

  • Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China

  • Sections